You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer
|
|---|---|
| Published in |
BMC Cancer, August 2016
|
| DOI | 10.1186/s12885-016-2636-z |
| Pubmed ID | |
| Authors |
Brian Won, Isa Mambetsariev, Ravi Salgia |
| Abstract |
We report the re-biopsied diagnosis of a patient with anaplastic lymphoma receptor tyrosine kinase (ALK)-positive lung adenocarcinoma successfully treated with ceritinib 450 mg/day taken with food following disease progression and gastrointestinal intolerance to crizotinib. A 74-year old female patient initially diagnosed with ALK-negative lung adenocarcinoma responded to initial standard chemotherapy. The patient was subsequently re-tested by next generation sequencing (NGS) and found to have ALK EIF2AK3-ALK fusion, and responded to crizotinib, but ultimately progressed and showed intolerance to this ALK inhibitor. She was then successfully treated with ceritinib 450 mg/day taken with food, has not suffered from any further gastrointestinal side-effects, and remains on ceritinib treatment after 12 months. Second-line ceritinib treatment, when administered at 450 mg/day with food, is both well tolerated and efficacious in a patient with previously treated lung adenocarcinoma who had discontinued crizotinib due to disease progression and gastrointestinal adverse effects (AEs). |
Mendeley readers
The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 16 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 2 | 13% |
| Researcher | 2 | 13% |
| Student > Master | 2 | 13% |
| Professor | 1 | 6% |
| Lecturer | 1 | 6% |
| Other | 2 | 13% |
| Unknown | 6 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 19% |
| Biochemistry, Genetics and Molecular Biology | 2 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 6% |
| Agricultural and Biological Sciences | 1 | 6% |
| Nursing and Health Professions | 1 | 6% |
| Other | 0 | 0% |
| Unknown | 8 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 January 2024.
All research outputs
#8,487,737
of 25,323,244 outputs
Outputs from BMC Cancer
#2,359
of 8,931 outputs
Outputs of similar age
#135,645
of 377,496 outputs
Outputs of similar age from BMC Cancer
#57
of 265 outputs
Altmetric has tracked 25,323,244 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,931 research outputs from this source. They receive a mean Attention Score of 4.8. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 377,496 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 265 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.